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Abstract: This work is focused on the ex vivo study of corneal permeation of two anti-inflammatory drugs: diclofenac, 
and flurbiprofen (as a model of hydrophilic and lipophilic drug, respectively) loaded to cyclodextrins or polymeric 
nanoparticles in order to determine differences in their corneal permeation against free drug or commercial eye drops. 
These studies were carried out in a corneal device designed and developed in our laboratory. In this work the habitual 
conditions for the permeation studies were modified to reproduce the behaviour when eye drops were administered. For 
this reason a new tetracompartmental pharmacokinetic model was developed. The complex formation of diclofenac with 
cyclodextrins and the flurbiprofen loaded to polymeric nanoparticles has been shown as effective procedures to remarka-
bly increase the bioavailability of the anti-inflammatory drugs. The efficiency of polymeric nanoparticles of Poly (D-L 
lactic-coglycolyc) acid and poly--caprolacton as intraocular targeting of NSAIDs has also been proved, being the latter 
polymer more effective to increase the flurbiprofen corneal permeation. The apparent corneal permeability coefficient of 
samples has been calculated getting a low permeation values for free drugs. 
INTRODUCTION 
  Nonsteroidal anti-inflammatory drugs (NSAIDs), like 
diclofenac and flurbiprofen, have been found to be viable 
alternatives to steroids in treating ocular inflammation. This 
therapy requires, due to low permeation rates and a rapid 
pre-corneal loss, a frequent application or highly concen-
trated eye drop formulations. The drugs must penetrate 
across the cornea, to reach therapeutic targets within the 
globe. In general, no more than five percent of drug, present 
in the precorneal area, crosses the cornea and arrives to in-
traocular tissues. The rest of the administered drug is 
dragged by the tear to the nasal conduit where it is elimi-
nated later by digestive tract. 
  The present research was focused on the ex vivo study of 
corneal permeation of two anti-inflammatory drugs (NSAIDs), 
frequently used in ocular pharmacology: diclofenac and flur-
biprofen. The corneal permeation of these free drugs was 
compared to the one of the diclofenac forming complexes 
with cyclodextrins or the flurbiprofen loaded to polymeric 
nanoparticles. 
MATERIALS AND METHODS 
  These studies were carried out in a corneal device de-
signed and developed in our laboratory for this research [1], 
based in the others previously described [2-4]. 
  The Fig. (1) shows the chamber used to measure corneal 
permeation in detail. 
  The principle of the apparatus is that the cornea of the 
rabbit is placed in a methacrylate chamber clamped between  
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two pieces so that the epithelial surface faces one compart-
ment (anterior or tear compartment) and the endothelial sur-
face the other (posterior or aqueous humor compartment). 
 
Fig. (1). Detail of the metacrylate chamber to clamp the cornea. 
  The Fig. (2) shows the entire setup of the system. The 
fluid contained in the anterior compartment can be ex-
changed continuously by means of a pump. The hydrostatic 
pressure in endothelial compartment can be chosen arbitrar-
ily and independently. The experimental temperature can be 
controlled continuously. 
  The transcorneal electrical potential can be measured and 
registered also continuously to check the vitality of the rabbit 
cornea [5, 6]. 
  Albino New Zealand rabbits weighing 1.8 to 2.2 kg, were 
used. After rabbits were sacrificed, the corneas were re-
moved and immediately mounted and clamped in the cham-
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Fig. (2). Entire setup of the corneal device for the study of corneal 
permeation. 
  The basic solutions were prepared from reagent grade 
chemicals as in the report of O’Brien and Edelhauser [7]. 
  The artificial tears solution (ATS), for the epithelial side 
of the cornea, was a Bicarbonate buffered Ringer's solution 
prepared previously and maintained at 4º C. Previously to 
perform experiment the above solution was warmed and was 
added 0.9 g L
-1 of glucose with magnetic stirring. 
  To prepare the artificial aqueous humor (AAH) for the 
endothelial side of the cornea takes the obtained ATS and 
add Glutathione 0.13 g L
-1 and Adenosine 0.09 g L
-1 at 37º C 
with stirring just before use. 
  The extraction of small volumes of the endothelial solu-
tion without loss of pressure was carried out by means of a 
syringe with a needle that crosses the cork of the endothelial 
compartment. Samples of 50 μL of the endothelial compart-
ment were taken at different times (between 5 minutes and 2 
hours) and then were analysed by Ultraviolet Absorption 
Spectroscopy. 
 Apparent  permeability  coefficients  (Papp)  were meas-
ured by previously described methods [8], according to this 
equation: 
  
where Q / t is the variation of drug amount, corresponding 
to the slope of the linear portion of the graphic (normally the 
first hour), 60 the conversion from minutes to seconds, A is 
the corneal surface (in this study 0,55 cm
2) and C0 the initial 
drug concentration in the epithelial side. 
CORNEAL PERMEATION WITHOUT WASHING PRO- 
CEDURE: TRI-COMPARTMENTAL MODEL 
  Most corneal penetration studies have been performed 
maintaining constant drug concentration in the artificial tear 
solution of the external or epithelial compartment. In this 
way the drug concentration at the internal or endothelial cor-
neal side, increases regularly following an exponential slope 
like as reflected in Fig. (4). 
  When there exists a constant flux of drug a simplified, 
but very precise, tricompartmental model can been used. 
This model has been developed based on the one proposed 
by Maurice [9]. It works with the following elements (Fig. 
3). 
  A constant external concentration Ce, a variable corneal 
concentration Cc, a variable internal concentration Ci, a 
transfer rate constant from the exterior to the cornea kl, and a 
transfer rate constant from the cornea to aqueous humor k2. 
 
Fig. (3). Tricompartmental model. Ce: constant external or epithe-
lial concentration, Cc: variable internal corneal concentration, Ci: 
variable internal or endothelial concentration, K1 and K2: transfer-
ence constants from epithelial compartment to cornea and from 
cornea to endothelial compartment, respectively. 
  In this work Ce and Ci are known. kl and k2 are un-
known, while Cc is not needed for the ca1culation. The drug 
flow is considered to be passive and against the concentra-
tion gradient. The statement of apparent corneal permeability 
can be laid out with the following two kinetic equations: 
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  Using the Pythagoras theorem, it can be seen that m1 is 
always negative, as m2 where all terms are negative, so we 
can use n1 and n2 as m1 and m2. Taking also into account that 
Cl (0) = 0 and Ci (t  ) = Ce the model is simplified obtain-
ing the equation in its final form: 
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  Were “t” is the variable time and n1 and n2 two pharma-
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immediate pharmacokinetic significance. It depends on the 
experimental conditions and on the product itself. 
  The apparent permeability for Sodium Diclofenac calcu-
lated by the slope of the graphic at sixty minutes was 9.55 · 
10
-4 cm/h (Fig. 4). 
CORNEAL PERMEATION WITH WASHING PRO-
CEDURE. TETRA-COMPARTMENTAL MODEL 
  When the drugs are administered as eye drops the tears 
wash quickly the corneal surface, so that the drug is pulled to 
the nasal conduit and its corneal permeation also diminishes 
quickly. 
  This behaviour was reproduced in our experiments sub-
jecting the initial endothelial drug solution to a continuous 
wash of artificial tear during the permeation measures. The 
graphic so obtained is shown in Fig. (4). 
  The apparent permeability calculated in this graphic by 
the slope at sixty minutes in both procedures have the values 
shown in the figure. 
  This model requires a more complex treatment as a tetra-
compartmental pharmacokinetic model. 
  In this model the statement of corneal permeability re-
quires three differential equations: 
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  The main variation of Ce is to wash by ATS so it can 
approach 
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  So the anterior equation of the tricompartmental model is 
reduced to the following: 
e i i i C k k C k k C k k C   =   +   + + 2 1 2 1 2 1 ) 2 (  
  And with a similar treatment that tricompartmental model 
let us to: 
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  Were “t” is also the variable time and n1, n2, A and B, 
pharmacokinetic parameters related to k1, k2 and k3. 
TRANSCORNEAL PERFUSION OF DICLOFENAC -
CYCLODEXTRIN COMPLEX 
  In ophthalmology, local drug administration in the form 
of topically applied low viscosity aqueous eye drop solutions 
is generally preferred. 
  Topically applied drugs must be, at least to some degree, 
soluble in the aqueous tear fluid. NSAIDs used to treat ocu-
lar inflammation are lipophilic water-insoluble compounds 
that have to be introduced into aqueous eye drop formula-
tions as water-soluble salts (like sodium diclofenac salt). 
However, they must also be somewhat lipid-soluble in order 
to penetrate the lipophilic corneal epithelium, through the 
corneal stroma and the lipophilic endothelium  into the 
aqueous humor. In both cases, ocular bioavailability is seri-
ously hampered by the low aqueous solubility or the hy-
drophilic properties of the penetrating molecules, respec-
tively. In other words, for successful formulation in an 
aqueous eye drop solution a drug must be both water-soluble 
(that is hydrophilic) and lipid-soluble (that is hydrophobic). 
  Cyclodextríns are novel, chemically stable adjuvants that 
enhance ocular bioavailability of ophthalmic drugs without 
affecting the barrier function of the eye  or increasing the 
viscosity of the aqueous, eye drop formulation. 
 
  
Fig. (4). Cornea permeation profile of Sodium Diclofenac 0.5 % solution without washing or with washing. 
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Fig. (5). Tetracompartmental model. Ce is now the variable exter-
nal concentration, Cr is the residual also variable concentration and 
K3 the transference constant from epithelial compartment to exte-
rior. Cc, Ci, K1 and K2 have the same significance as the anterior 
model. 
  Cyclodextrins are a group of structurally related natural 
products formed during bacterial digestion of cellulose. 
These cyclic olígosaccharides consist on linked glu-
copyranose units with a hydrophilic outer surface and a lipo-
philic central cavity. The natural  and -cyclodextrins 
consist on six, seven and eight glucopyranose units, respec-
tively. The internal cavity allows to lodge drug molecules 
with adequate dimensions [10]. 
In Fig. (6) the tridimensional structure of the diclofenac/  
cyclodextrin complex obtained by molecular modelling can 
be seen in our laboratory. 
  
Fig. (6). Molecular modelling obtained in our laboratory of the 
diclofenac –cyclodextrin complex [1]. 
  The cyclodextrin complexation of a drug molecule 
changes the physico-chemical properties of the drug, such as 
its aqueous solubility and chemical stability. Since the cy-
clodextrin molecule is hydrophilic on the outside, the com-
plex formation usually increases the water-solubility of lipo-
philic water-insoluble drugs. 
  Thus, it is possible through cyclodextrin complexation to 
formulate lipophilic water-insoluble molecules as aqueous 
eye drop solutions. Furthermore, the chemical stability of the 
drug molecule is enhanced by the formation of the inclusion 
complex. 
  If the complex is located in close approximation to a 
lipophilic biological membrane (such as the eye cornea), the 
guest may be transferred to the matrix with the highest affin-
ity. Importantly, since no covalent bonds are formed or bro-
ken during the guest-host complex formation, the complexes 
are in dynamic equilibrium with free drug and cyclodextrin 
molecules [11]. So, the hydrophilic cyclodextrins act as true 
carriers by keeping the lipophilic water-insoluble drug mole-
cules in solution and delivering them to the membrane sur-
face where the drug moves from the cyclodextrin cavity into 
the lipophilic membrane due to the membrane affinity to 
lipophilic drugs. The relatively lipophilic membrane has low 
affinity to large hydrophilic cyclodextrin molecules or hy-
drophilic drug/cyclodextrin complexes which remain in the 
aqueous exterior tear fluid [12]. 
  To obtain the diclofenac/-cyclodextrin complex 376 mg 
of sodium diclofenac and 1135 mg of -cyclodextrin were 
mixed in a mortar. Then a few drops of water were added 
kneading during 15-30 min. to obtain a uniform paste. The 
resulting dough was poured on a metallic surface and dried 
in a furnace at 40º C during 24 hours. The dried product was 
crushed in a mortar and sieved to obtain a fine powder. The 
concentration of the diclofenac in the complex was deter-
mined by UV spectroscopy. Solutions of the diclofenac/-
cyclodextrin complex so prepared containing 0.1% of di-
clofenac in ATS were obtained to measure the drug corneal 
permeation. 
  The graphic of Fig. (7) reflects the corneal permeations 
of sodium diclofenac 0.1 percent solution in artificial tear 
with tears washing and the solution in this dissolvent of the 
diclofenac/ -cyclodextrin complex at the same diclofenac 
concentration and identical procedure. It shows an important 
increase of corneal permeation with the latter. 
  The apparent permeability coefficients calculated in this 
graphic by the slope at sixty minutes in both formulations are 
4.13·10
-4 cm/h for the sodium diclofenac solution and 
2.57·10
-3 cm/h. for the diclofenac / -cyclodextrin complex. 
This reflects that the amount of diclofenac transferred 
through the cornea is six times higher when the drug is form-
ing a complex with -cyclodextrin. 
CORNEAL PERMEATION OF FLURBIPROFEN 
NANOPARTICLES 
  Nanoparticles are polymeric particles smaller than one 
micrometer that can load drug to drive it to the site of action 
(organ or tissue) improving its bioavailability. 
  There are two forms of nanoparticles: nanospheres and 
nanocapsules. Nanospheres have a rigid structure forming a 
polymeric network or matrix. The drug is adsorbed on the 
surface, dissolved or included in the matrix. Nanocapsules 
have vesicular structure formed by a polymeric cover and a 
lipid nucleus (or core). The drug is generally solved or in-
cluded in the nucleus. 
  Polymeric nanoparticles can improve the specificity of 
action, cellular penetration, and protection against the inacti-
vation of drugs. The main interest of these nanosystems is 
the possibility to modify the pharmacokinetic behaviour of 
drugs. 
  In this work the corneal permeation of flurbiprofen, a 
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different polymers: polylactic-polyglycolic acid and poly--
caprolacton were assayed. 
  Flurbiprofen (FB), loaded nanospheres of the above 
named polymers were prepared. They were made by the sol-
vent displacement technique described by Fessi and collabo-
rators [13]. 
 Brieﬂy, an organic solution of 90 mg of polymer in 25 
mL of acetone containing FB (from 0.16 to 1.84 mg/mL) 
was poured, under moderate stirring into 50 mL of an aque-
ous solution adjusted to the desired pH value (2.82– 6.18) 
from 6.60 to 23.40 mg/mL of poloxamer 188 (P188). Ace-
tone was then evaporated and the volume of NPs dispersion 
was concentrated to 10 mL under reduce pressure (Bu¨ chi 
B-480, Flawil, Switzerland). Empty NPs with or without 
P188 were prepared according to the same procedure but 
omitting the addition of FB in the organic phase. Table 1 
describes the physicochemical parameters of Flurbiprofen 
loaded to polylactic-glycolic acid and poly--caprolacton- 
nanospheres prepared at the same concentration as the com-
mercial eye drops to perform the ex vivo permeation studies. 
Table  1.  Composition and Physicochemical Properties of 
Flurbiprofen Loaded Nanospheres of Polylactic-
Glycolic Acid (FB-PLGA) and Poly--Caprolacton 
(FB-PCL)  
 
Nanospheres  Zav ± SD (nm)  PI ± SD  EE ± SD (%) 
FB-PLGA  209.9 ± 6.4  0.039 ± 0.027  85.94 ± 1.3 
FB-PCL  200.1 ± 7.1  0.060 ±0.019  97.16 ±2.1 
Zav: Average particle size. PI: Particle size distribution. EE: Entrapment efficiency. SD: 
Standard deviation. 
  All formulations showed an average particle size near to 
200 nanometers which is appropriate for ophthalmic applica-
tion. The particle size distribution was very narrow in all 
cases as the polidispersity index was less than 0.1 (zero point 
one), corresponding to monodisperse systems. The entrap-
ment efficiency of these nanospheres was found to be around 
eighty five per cent for Flurbiprofen – polylactic-glycolic 
acid and around ninety seven per cent for Flurbiprofen 
loaded poly--caprolacton [14]. 
  Flurbiprofen -loaded polylactic-glycolic acid or poly--
caprolacton nanospheres containing Flurbiprofen were tested 
and compared with the free drug solution in phosphate buffer 
solution, pH 7.4. 
 The  transcorneal  permeation  profile of flurbiprofen is 
shown in Fig. (8). 
  The permeation coefficient values calculated for each 
formulation confirmed these results. Flurbiprofen -loaded 
polymer nanoparticles showed a significantly higher drug 
permeation capability compared with the drug. 
Table  2.  Apparent Permeation Values of Flurbiprofen Free 
Drug and Loaded Nanospheres 
 
Flurbiprofen   Papp (cm/s x 10
6)  
Free drug  2.48 ± 1.06 
PLGA NPs  18.98 ± 0.65 
PECL NPs  9.78 ± 12.19 
Flurbiprofen - poly--caprolacton nanospheres reveal a major permeation coefficient 
than polylactic-glycolic acid nanospheres. 
 
  
Fig. (7). Cornea permeation profile of Sodium Diclofenac 0.5% free drug solution and of the Diclofenac/ -cyclodextrin complex at the same 
diclofenac concentration with washing procedure. 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160
t (min)
Sodium Diclofenac 0.5 % with washing                    
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CONCLUSIONS 
  A useful procedure to determine the corneal drug per-
meation has been developed. 
  The formation of NSAIDs with cyclodextrins has been as 
an a effective procedure to increase remarkably the bioavail-
ability of the anti-inflammatory drugs. 
  The efficiency of polymeric nanoparticles of polylactic-
polyglycolic acid and the poly--caprolacton as intraocular 
targeting of NSAIDs has also been proved, being the latter 
polymer more effective to increase the corneal permeation of 
the assayed drug flurbiprofen. 
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Fig. (8). Corneal permeation of flurbiprofen loaded nanospheres. 
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